SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)					1 Months Ended			12 Months Ended
	Jul. 02, 2021 USD ($)	Jun. 07, 2021 shares	Feb. 17, 2021 USD ($) $ / shares shares	Mar. 18, 2020 USD ($) $ / shares shares	Jul. 23, 2018 USD ($)	Oct. 19, 2017 USD ($)	Oct. 31, 2015	Dec. 31, 2021 USD ($) item $ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares	Dec. 31, 2019 shares	Aug. 25, 2021 $ / shares	Dec. 01, 2016
Significant Accounting Policies [Line Items]
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares								$ 0.001	$ 0.001
Shares Issued, Price Per Share | $ / shares			$ 4.60
Share price | $ / shares			$ 4.60
Gross proceeds			$ 40,200,000					$ 8,575,000	$ 4,867,000
Number of shares issued (in shares) | shares			8,749,999
Proceeds from private placement				$ 41,300,000
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares								28,502,017	22,850,682	7,838,120
Operating Lease, Right-of-Use Asset								$ 4,960,000	$ 5,567,000
Operating Lease, Liability								5,583,000
Accounts receivable - Trade								3,442,000	$ 2,000,000
Fiocruz [Member]
Significant Accounting Policies [Line Items]
Accounts receivable - Trade								2,200,000
Chiesi [Member]
Significant Accounting Policies [Line Items]
Accounts receivable - Trade								$ 1,200,000
2021 Notes
Significant Accounting Policies [Line Items]
Interest rate (as a percent)								7.50%			7.50%	7.50%
Aggregate principal amount								$ 0
2024 Notes
Significant Accounting Policies [Line Items]
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares											$ 0.001
Interest rate (as a percent)								7.50%			7.50%
Aggregate principal amount								$ 28,750,000
Minimum
Significant Accounting Policies [Line Items]
Tax Rate Assumption Related To Deferred Tax Difference Reversal								23.00%
Maximum
Significant Accounting Policies [Line Items]
Tax Rate Assumption Related To Deferred Tax Difference Reversal								21.00%
Amended Pfizer Agreement | Protalix Bio Therapeutics Incorporation [Member] | Brazil [Member]
Significant Accounting Policies [Line Items]
Collaborative Arrangement Revenues Expenses Sharing Percentage							100.00%
Chiesi US Agreement and Chiesi Ex US Agreement [Member]
Significant Accounting Policies [Line Items]
Non-refundable Payment Receivable						$ 25,000,000.0		$ 50,000,000.0
Revenue, Performance Obligation, Number | item								2
Chiesi US Agreement [Member]
Significant Accounting Policies [Line Items]
Non-refundable Payment Receivable					$ 25,000,000.0	25,000,000.0
Additional Amounts Payable To Cover Development Costs					$ 20,000,000.0
Chiesi US Agreement [Member] | Minimum
Significant Accounting Policies [Line Items]
Payment On Net Sales Percentage					15.00%			15.00%
Chiesi US Agreement [Member] | Maximum
Significant Accounting Policies [Line Items]
Payment On Net Sales Percentage					40.00%			40.00%
Chiesi Ex US Agreement [Member]
Significant Accounting Policies [Line Items]
Non-refundable Payment Receivable						25,000,000.0
Additional Amounts Payable To Cover Development Costs						$ 25,000,000.0
Chiesi Ex US Agreement [Member] | Minimum
Significant Accounting Policies [Line Items]
Payment On Net Sales Percentage						15.00%		15.00%
Chiesi Ex US Agreement [Member] | Maximum
Significant Accounting Policies [Line Items]
Payment On Net Sales Percentage						35.00%		35.00%
ATM Shares
Significant Accounting Policies [Line Items]
Sale Of Stock Maximum Offering Price	$ 20,000,000.0
Number of shares issued (in shares) | shares								0
Private Placement
Significant Accounting Policies [Line Items]
Share price | $ / shares				$ 2.485
Number of shares issued (in shares) | shares		173,816		17,604,423					200,000
Purchase price (in dollars per share) | $ / shares				$ 2.485
Number of warrants issued (in shares) | shares				17,604,423
Exercise price of warrants (in dollars per share) | $ / shares				$ 2.36
Exercise of warrants, commencement period				6 months
Term of warrants				5 years
Proceeds from private placement				$ 43,700,000